MiNK Presentation SITC 2021
Marco A. Purbhoo, Burcu Yigit, Darrian Moskowitz, Ayat Alsaraby, Maurice Kirby, Anitha Swarna, Valeriia Nasonenko, Ilya Mishchenko, Sonia De Munari, Waldo Ortuzar, Koen Van Besien, Don Stevens, Terese Hammond, Xavier Michelet, Marc van Dijk
November 12, 2021
Single infusion of agenT-797 demonstrated a pronounced survival rate of 77% in mechanically ventilated elderly COVID-19 patients with moderate to severe ARDS. 13 patients have been treated to date, with 8 patients discharged and 2 patients ongoing. This represents an improvement compared to a National average of approximately 40 % (range 24-53%) for intubated or mechanically ventilated patients during time of enrollment.
77% overall survival in intubated ICU Patients with ARDS (COVID-19)
Dose Level
Agent-797
(No. cells)
No. Patients
No. Discharged
No. Deaths
1
100 x 106
3
2
1
2
300 x 106
4
3
1
3
1000 x 106
6
3
1
Dose Level 1
Agent-727(No. cells): 100 x 1016
No. Patients: 3
No. ongoing: ---
No. discharged: 2
No. deaths: 1
Dose Level 2
Agent-727(No. cells): 300 x 1016
No. Patients: 4
No. ongoing: ---
No. discharged: 3
No. deaths: 1
Dose Level 3
Agent-727(No. cells): 1000 x 1016
No. Patients: 6
No. ongoing: ---
No. discharged: 4
No. deaths: 1
Phase 1 study to evaluate the safety and efficacy of agenT-797, an unmodified, allogeneic iNKT cell therapy, in patients with acute respiratory distress syndrome (ARDS) secondary to COVID-19, requiring mechanical ventilation.
Baseline Demographics
Characteristic
All Patients
(n=13)
Media Age Range
69 (49-77)
Sex, n (%)
Male
3 (23)
Female
10 (77)
Co-medications, n
Remdesivir
Steroids
5
Remdesivir
Steroids
Tocilizumab
5
Other
3
MiNK developed a digital PCR-based method to characterize agent-797 in patients; analyses of tissue distribution, persistence, and functional capacity of agent-797 are underway.
Key observations:
Invariant Natural Killer T (iNKT) cells are key effectors and regulators of immune responses, making them an ideal immunotherapy.
In cancer, iNKT cells reshape the tumor microenvironment:
In viral lung disease, iNKT cells:
MiNK’s iNKT cell manufacturing is scalable